Evaluation of high density lipoprotein as a circulating biomarker of Gaucher disease activity
- 191 Downloads
Circulating biomarkers are important surrogates for monitoring disease activity in type I Gaucher disease (GD1). We and others have reported low high-density lipoprotein (HDL) in GD1. We assessed HDL cholesterol as a biomarker of GD1, with respect to its correlation with indicators of disease severity and its response to imiglucerase enzyme replacement therapy (ERT). In 278 consecutively evaluated GD1 patients, we correlated HDL cholesterol, chitotriosidase, and angiotensin-converting enzyme (ACE) with indicators of disease severity. Additionally, we measured the response of these biomarkers to ERT. HDL cholesterol was negatively correlated with spleen volume, liver volume, and GD severity score index; the magnitude of this association of disease severity with HDL cholesterol was similar to that for ACE and for chitotriosidase. Within individual patients monitored over many years, there was a strikingly strong correlation of HDL with liver and spleen volumes; there was a similarly strong correlation of chitotriosidase and ACE with disease severity in individual patients monitored serially over many years (chitotriosidase r = 0.96 to 0.98, ACE r = 0.88 to 0.94, and HDL r = −0.84 to −0.94, p < 0.001). ERT for 3 years resulted in a striking increase of HDL while serum levels of chitotriosidase and ACE decreased. Our results reveal markedly low HDL cholesterol in untreated GD1, a correlation with indicators of disease severity in GD1, and a rise towards normal after ERT. These findings suggest HDL cholesterol merits inclusion within the “biomarker basket” for monitoring of patients with GD1.
KeywordsEnzyme Replacement Therapy Gauche Disease Familial Hypercholesterolemia Reverse Cholesterol Transport Spleen Volume
We are grateful to our patients for their participation in these studies. P.K.M. was supported by an NIDDK K24DK066306 Mid-Career Clinical Investigator award and an Investigator Initiated Study on Biomarker Discovery and Validation in Gaucher Disease by Genzyme Corporation. P.S. was supported by a Lysosomal Storage Fellowship Award from Genzyme Corporation.
- Grabowski GA, Petsko GA, Kolodny E (2010) Gaucher disease. In: Valle D, Beaudet A, Vogelstein B et al (eds) OMMBID. Part 16: lysosomal disorders, chapter 146. http://www.ommbid.com/OMMBID/the_online_metabolic_and_molecular_bases_of_inherited_disease/b/fulltext/part16/ch146 12/11/2010
- Langeveld M, Ghauharali KJ, Sauerwein HP et al (2008) Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. Clin Endocrinol Metab 93:845–851Google Scholar
- Mistry PK, Liu J, Yang M et al (2010) Glucocerebrosidase gene-deficient mouse recapitulates Gaucher disease displaying cellular and molecular dysregulation beyond the macrophage. Proc Natl Acad Sci 107(45):19473–10478Google Scholar
- Mistry PK, Cappellini MD, Lukina C et al (2011) A reappraisal of Gaucher disease—diagnosis and disease mangement algorithms. Am J Hematol 86:110–115Google Scholar
- Tuchman LR, Suna H, Carr JJ (1956) Elevation of serum acid phosphatase in Gaucher’s disease. J Mt Sinai Hosp NY 23:227Google Scholar
- von Eckardstein A, Nofer J, Assmann G (2001) High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 21:13–27Google Scholar